A Study of S5G4T-1 in the Treatment of Papularpustular Rosacea

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
In this Phase 3, double‐blind, randomized, vehicle‐controlled, parallel‐group pivotal study, participants will be admitted only after a written informed consent has been obtained and after all inclusion/exclusion criteria have been met. Male and female participants at least 18 years of age with moderate or severe papulopustular rosacea will be eligible for enrollment for daily treatment with S5G4T‐1 or its vehicle for 12 weeks.
Epistemonikos ID: f5700804282b08a2cf89c7595c938b3170e5854d
First added on: May 21, 2024